Abstract:Background and purpose: Systematic treatment for breast cancer largely depends on the status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Discordance in ER, PR and HER2 status between primary breast cancer and distant metastases has been observed in a proportion of patients in previous studies. Liver is one of the frequent metastatic sites of breast cancer. Currently, limited data are available on the receptor conversion between primary breast cancer and matched liver metastases. This study aimed to investigate the prevalence, risk factors and prognostic impact of receptor conversion between primary breast cancer and paired liver metastases. Methods: The data of breast cancer patients who had pathologically confirmed liver metastases from January 2013 to May 2020 at Fudan University Shanghai Cancer Center were retrospectively collected. A total of 353 patients with ER, PR and HER2 status available on both primary breast cancer and matched liver metastases were finally included in this study. ER, PR and HER2 status were interpreted according to the most updated American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. The evolution of receptor status and phenotype from primary to metastatic breast cancer was illustrated using Sankey diagrams. Kappa coefficient and McNemar’s test were used to assess the agreement on receptor status between primary breast cancer and liver metastases. The Kaplan-Meier curves were plotted and survival differences across each group were assessed by log-rank test. Multivariate analyses were performed based on the COX proportional hazard regression model. Results: The total discordance rate of ER, PR and HER2 was 19.5%, 39.4% and 4.8%, respectively (Kappa coefficient: 0.569, 0.258 0.876). In de novo stage Ⅳ patients, the discordance rate of ER, PR and HER2 was 15.2%, 28.3% and 2.2%, respectively. Multivariate analysis showed that previous endocrine therapy before liver re-biopsy was an independent risk factor of PR discordance. None of the variables of interest was found to be associated with discordance in ER or HER2 status. Additionally, 37.9% of the HER2-0 tumors converted to HER2-low. A trend of increase in triple-negative and decrease in hormone receptor (HR)+/HER2- cases were observed in liver metastases. Patients with HR+/HER2- primary breast cancer who converted to triple-negative in liver metastases had a significantly shorter overall survival (OS) than those with consistent HR+/HER2- subtype. Patients with the same subtype in liver metastases shared similar OS. Conclusion: This study confirmed discordance in ER, PR and HER2 status between primary breast cancer and liver metastases. The prognosis of breast cancer patients was determined mainly by the subtype in metastases rather than that in primary disease. Our study underlined the necessity of liver re-biopsy in de novo stage Ⅳ patients with liver metastases. Over one-third of HER2-0 patients converted to HER2-low in liver metastases after reassessment, which enabled them to be treated with new antibody-drug conjugate (ADC).

Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Breast Cancer Primary Tumor ER Expression Pattern Predicts Its Expression Concordance in Matched Synchronous Lymph Node Metastases

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

[Discordance of Estrogen Receptor (ER), Progestin Receptor (PR), and HER-2 Receptor Statuses Between Primary and Metastatic Focuses of Breast Cancer].

Receptor discordance between primary breast cancer and liver metastases

HER2 Changes to Positive after Neoadjuvant Chemotherapy in Breast Cancer: A Case Report and Literature Review

Her2 Expression in Primary Gastric Cancers and Paired Synchronous Lymph Node and Liver Metastases. A Possible Road to Target Her2 with Radionuclides

EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases

Human Epidermal Growth Factor Receptor 2 Protein Expression Between Primary Breast Cancer and Paired Asynchronous Local-Regional Recurrences.

The primary metastatic sites in 176 patients with HER2 positive breast cancer

A Comparison Of Tumor Characteristics Between Er Plus /Pr Plus And Er Plus /Pr- Breast Tumors In Chinese Women

Retrospective study of the differences of biomarker expression between primary lesions of breast cancer and corresponding lymph node metastases

Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2‐Positive Breast Cancer

Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study

The Importance of Biopsy in Clinically Diagnosed Metastatic Lesions in Patients with Breast Cancer

Clinical Research on ER, PR Status with Recurrence and Distant Metastatic Site in Primary Breast Cancer

Alterations in three biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor 2) and the Ki67 index between primary and metastatic breast cancer lesions.

Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy

HER2‐low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis